229 related articles for article (PubMed ID: 28919384)
1. The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene.
Tsume Y; Igawa N; Drelich AJ; Amidon GE; Amidon GL
J Pharm Sci; 2018 Jan; 107(1):307-316. PubMed ID: 28919384
[TBL] [Abstract][Full Text] [Related]
2. The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
Tsume Y; Matsui K; Searls AL; Takeuchi S; Amidon GE; Sun D; Amidon GL
Eur J Pharm Sci; 2017 May; 102():126-139. PubMed ID: 28263914
[TBL] [Abstract][Full Text] [Related]
3. The Introduction of a New Flexible In Vivo Predictive Dissolution Apparatus, GIS-Alpha (GIS-α), to Study Dissolution Profiles of BCS Class IIb Drugs, Dipyridamole and Ketoconazole.
Tsume Y; Patel S; Wang M; Hermans A; Kesisoglou F
J Pharm Sci; 2020 Nov; 109(11):3471-3479. PubMed ID: 32888960
[TBL] [Abstract][Full Text] [Related]
4. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents.
Matsui K; Tsume Y; Amidon GE; Amidon GL
Mol Pharm; 2015 Jul; 12(7):2418-28. PubMed ID: 25985298
[TBL] [Abstract][Full Text] [Related]
6. Revisiting Supersaturation of a Biopharmaceutical Classification System IIB Drug: Evaluation via a Multi-Cup Dissolution Approach and Molecular Dynamic Simulation.
Gan Y; Xu Y; Zhang X; Hu H; Xiao W; Yu Z; Sun T; Zhang J; Wen C; Zheng S
Molecules; 2023 Oct; 28(19):. PubMed ID: 37836805
[TBL] [Abstract][Full Text] [Related]
7. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
[TBL] [Abstract][Full Text] [Related]
8. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
[TBL] [Abstract][Full Text] [Related]
9. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
10. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
11. A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs.
Macheras P; Iliadis A; Melagraki G
Eur J Pharm Sci; 2018 May; 117():98-106. PubMed ID: 29425862
[TBL] [Abstract][Full Text] [Related]
12. Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): An in vitro-in silico-in vivo approach.
Hens B; Bermejo M; Tsume Y; Gonzalez-Alvarez I; Ruan H; Matsui K; Amidon GE; Cavanagh KL; Kuminek G; Benninghoff G; Fan J; Rodríguez-Hornedo N; Amidon GL
Eur J Pharm Sci; 2018 Mar; 115():258-269. PubMed ID: 29378253
[TBL] [Abstract][Full Text] [Related]
13. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
[TBL] [Abstract][Full Text] [Related]
14. Utilization of Gastrointestinal Simulator, an in Vivo Predictive Dissolution Methodology, Coupled with Computational Approach To Forecast Oral Absorption of Dipyridamole.
Matsui K; Tsume Y; Takeuchi S; Searls A; Amidon GL
Mol Pharm; 2017 Apr; 14(4):1181-1189. PubMed ID: 28231003
[TBL] [Abstract][Full Text] [Related]
15. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
16. In vitro-in vivo correlation of the effect of supersaturation on the intestinal absorption of BCS Class 2 drugs.
Higashino H; Hasegawa T; Yamamoto M; Matsui R; Masaoka Y; Kataoka M; Sakuma S; Yamashita S
Mol Pharm; 2014 Mar; 11(3):746-54. PubMed ID: 24460473
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a three compartment in vitro gastrointestinal simulator dissolution apparatus to predict in vivo dissolution.
Takeuchi S; Tsume Y; Amidon GE; Amidon GL
J Pharm Sci; 2014 Nov; 103(11):3416-3422. PubMed ID: 25251982
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology.
Sun L; Sun J; He Z
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):471-487. PubMed ID: 27447171
[TBL] [Abstract][Full Text] [Related]
19. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
Hens B; Pathak SM; Mitra A; Patel N; Liu B; Patel S; Jamei M; Brouwers J; Augustijns P; Turner DB
Mol Pharm; 2017 Dec; 14(12):4321-4333. PubMed ID: 28817288
[TBL] [Abstract][Full Text] [Related]
20. Understanding In Vivo Dissolution of Immediate Release (IR) Solid Oral Drug Products Containing Weak Acid BCS Class 2 (BCS Class 2a) Drugs.
Li M; Zhang X; Wu D; Anand O; Chen H; Raines K; Yu L
AAPS J; 2021 Oct; 23(6):113. PubMed ID: 34704158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
